01
Vesper Bio has a leadership position in exploiting sortilin receptor biology to develop therapies that have a critical unmet medical need.
02
Vesper Bio is a clinical stage biotech company which uses a sortilin inhibitor to rebalance levels of progranulin in patients where the sortilin receptor would otherwise reduce circulating and extracellular progranulin, contributing to disease.
03
Vesper Bio are pioneers in sortilin biology, with a strong background in biopharma, backed by an exceptional multi-national scientific advisory board, which consists of leading key opinion leaders.
Our approach
Our scientific founders have pioneered the exploration of the structure and function of the Vps10p family of proteins for decades. Critical insight has emerged from understanding the key protein-protein interactions and what drives them. With this insight, we have focussed on the discovery of protein-protein interaction inhibitors. We have achieved this through a combination of cutting-edge structure-based design, informed by numerous high resolution ligand-target X-ray co-crystal structures, and augmented by extensive collaboration with leading academic labs.